NCT06990620View on ClinicalTrials.gov

TACE Plus Ivonescimab for Unresectable Non-Metastatic HCC

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

56

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

December 31, 2027

Conditions

Hepatocellular Carcinoma (HCC)

Interventions

COMBINATION_PRODUCT

TACE+AK112

TACE+AK112 (PD-1/VEGF bi-antibody, 20mg/kg, ivgtt, Q3W)

All Listed Sponsors

lead

Fudan University

OTHER